3 'Strong Buy' Stocks Rallying In Trade War Volatility

As global trade tensions play havoc with the financial markets, one strategy is to consider stocks with relatively large domestic sales exposure. This is the tactic recommended by Goldman Sachs. “Below the surface of the market, trade conflict would benefit the performance of the most domestic-facing U.S. stocks relative to the most foreign-facing firms,” the firm says.  So with this in mind, we extracted three intriguing stock ideas with 100% domestic sales. As you will see, all of these stocks have little to no international exposure- so it’s no surprise that these stocks have rallied in the last few days. That’s despite President Trump’s announcement of further tariffs on $200 billion of Chinese goods.

Even better, these are stocks with big support from TipRanks’ top analysts. We rank analysts based on their success rate and average return so that you can follow the advice of analysts who consistently crush the market. As you will see below, all three stocks boast a ‘Strong Buy’ analyst consensus rating. This is based only on ratings from the last three months, giving you the most up-to-date picture of the market.

Let’s take a closer look now:

CVS Health (CVS)

100% US Sales

Drugstore giant CVS Health has 100% support from top analysts right now. In the last three months, the stock has received three back-to-back buy ratings from the Street’s best-performing analysts. And luckily for investors, on average these analysts are predicting 23% upside potential from the current share price.

CVS Health is currently fighting hard to push through a massive $69 billion deal with one of the US’s biggest health insurers: Aetna (NYSE: AET). Crucially, the stock has just received a critical upgrade from Citigroup’s Ralph Giacobbe (Profile & Recommendations). He believes deal integration and competitive risk from Amazon are “overstated particularly in the context of heavily discounted valuation.” And looking further ahead, he is confident that the integration of Aetna will resonate with employers and individuals. As a result, the analyst ramped up his price target on CVS from $68 to $81.

1 2 3
View single page >> |

Disclaimer: TipRanks is an independent cloud based service that measures and ranks digitally published financial advice. TipRanks' natural language processing (NLP) algorithms aggregate and ...

more
How did you like this article? Let us know so we can better customize your reading experience. Users' ratings are only visible to themselves.

Comments

Leave a comment to automatically be entered into our contest to win a free Echo Show.